External skin preparation component incorporating fine needle-like or columnar taurine crystals
By recrystallizing taurine at extremely low solubility states, fine needle-shaped or columnar crystals are prepared, which solves the problem of difficult to control the crystal size and shape in traditional methods, and improves the use experience of skin topical preparations and the efficacy of taurine.
Patent Information
- Application Number
- CN202380029257.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-04-15
- Filing Date
- 2023-04-14
- Publication Date
- 2024-11-08
AI Technical Summary
Traditional taurine manufacturing methods fail to effectively control the size and shape of the crystals, resulting in the skin topical preparations that feel rough when used, affecting the user experience.
By mixing or contacting the aqueous taurine solution with a liquid substance with a low solubility, a very low solubility state is formed, and taurine is recrystallized in this state to produce fine needle-like or columnar taurine crystals, and control it The size is within the range of thickness below 150 microns and length below 3000 microns.
The obtained fine needle-like or columnar taurine crystals make the skin external preparation not irritating the skin, have a smooth and delicate touch, and improves the skin permeability and medicinal effect of taurine.
Smart Images

Figure BDA0005052825430000161 
Figure BDA0005052825430000171 
Figure BDA0005052825430000172
Abstract
Description
Technical Field
[0001] The present invention relates to a method for preparing fine needle-shaped or columnar taurine crystals and their use. Specifically, the present invention relates to a skin external preparation containing taurine and a method for enhancing the skin permeability and efficacy of taurine. Background Art
[0002] Taurine is a compound with the chemical name of 2-aminoethanesulfonic acid, and is a sulfur-containing free amino acid with the highest content in biological cells. It is known that taurine, unlike the amino acids that constitute proteins, has a variety of pharmacological effects, including vitamin and hormone effects, as well as pharmacological effects in the brain and nervous system, circulatory system, liver and biliary system, etc. In recent years, it has been found that taurine plays an important role in the moisturizing properties of the skin.
[0003] There are many known methods for producing taurine, including extraction from aquatic products, various organic synthesis methods, etc. For example, Patent Document 1 describes a method for producing high-purity taurine, and Patent Document 2 describes a method for producing taurine at a high yield.
[0004] Regarding the technology of refining taurine, the taurine refining method described in Patent Document 3 first allows a solution containing taurine and inorganic salts to contact a porous solid material with a molecular sieve effect, so that taurine is adsorbed on the porous solid material, separated from the inorganic salt, and then an organic solvent (which may contain water) is used to separate the taurine adsorbed on the porous solid material. Regarding the method of refining taurine with a high yield, the known traditional technology is to add ethanol for crystallization. In other words, this method is to precipitate taurine crystals in an ethanol aqueous solution when using a hot water or warm water extraction solution of a natural product (aquatic products, etc.) and a synthetic reaction termination solution to purify taurine, and obtain the final taurine crystals by filtering and drying. As described in Patent Document 4, a taurine-containing reaction solution is obtained through a manufacturing process, and ethanol is added therein for treatment to separate or remove impurities. Regarding the purification method of the obtained crystals, for example, the taurine purification method described in Patent Document 5 comprises separating the crystals precipitated by crystallization from the crystallization mother liquor, treating the crystals with an ethanol aqueous solution containing hydrochloric acid, and then treating the crystals with an ethanol aqueous solution not containing hydrochloric acid.
[0005] References
[0006] Patent Literature
[0007] [Patent Document 1] Japanese Patent Application Publication No. 2021-172652
[0008] [Patent Document 2] Japanese Patent Publication No. 2021-063060
[0009] [Patent Document 3] Japanese Patent Publication No. 2005-232026
[0010] [Patent Document 4] Japanese Patent Publication No. 1994-192209
[0011] [Patent Document 5] Japanese Patent Publication No. 1995-017943 Summary of the invention
[0012] Technical problem to be solved by the invention
[0013] Conventional production and purification methods disclose a technique for obtaining high-purity taurine crystals at a high yield, but do not disclose a technique for controlling the size and shape of the crystals.
[0014] Taurine crystals are directly incorporated into skin topical preparations, so that the fine needle-shaped crystals penetrate the stratum corneum with skin barrier function and form micropores on the stratum corneum, which is expected to promote the percutaneous absorption of taurine itself and the medicaments in the topical preparations. When taurine crystals are directly incorporated into skin topical preparations, the crystal sizes are different and the feeling of use is greatly changed. If the crystal size exceeds a certain range, the skin topical preparation will feel very rough when used, and the feeling of use of the skin topical preparation is unpleasant. Therefore, in order not to irritate the skin during use and feel smooth and delicate, it is desired to obtain fine needle-shaped crystals below a specific size.
[0015] Technical Solution
[0016] In order to solve the above problems, the inventors of this case have made continuous efforts to study and found that by adding a taurine aqueous solution to a liquid substance with low taurine solubility, or slowly injecting a liquid substance with low taurine solubility into a taurine aqueous solution to form an interface, a state of extremely low solubility is created, and taurine is recrystallized in this state, fine needle-shaped or columnar taurine crystals with controlled crystal shapes can be produced. It is also found that the fine needle-shaped or columnar taurine crystals obtained by this method are within the range of 5 to 150 microns in thickness and 100 to 3000 microns in length, and the skin external preparation component containing such taurine crystals can provide a preparation that does not have the rough feeling of crystals and gives the dry and refreshing feeling of fine needle-shaped or columnar crystals.
[0017] The present invention is as follows:
[0018] [1] A component of a skin external preparation characterized by containing fine needle-shaped or columnar taurine crystals having a thickness of less than 150 μm and a length of less than 3000 μm.
[0019] [2] The composition for external skin preparation as described in [1], further characterized by containing a useful substance.
[0020] [3] The component for external skin preparation as described in [1] or [2], characterized in that the aforementioned fine needle-shaped or columnar taurine crystals are obtained by crystal growth in an environment where a taurine aqueous solution is mixed or brought into contact with a liquid substance with a low taurine solubility.
[0021] [4] The skin external preparation component according to [3], characterized in that the liquid substance having a low taurine solubility is a water-soluble organic solvent.
[0022] [5] A method for producing fine needle-shaped or columnar taurine crystals, comprising the step of growing crystals in an environment where a taurine aqueous solution is mixed or brought into contact with a liquid substance with a low taurine solubility.
[0023] [6] The production method as described in [5] is characterized in that the taurine concentration in the aqueous solution is 3 to 28w%.
[0024] [7] The production method as described in [5] or [6] is characterized in that the ratio of the amount of the liquid substance with low taurine solubility to the total amount of the taurine aqueous solution is less than 50w%.
[0025] [8] A production method as described in any one of [5] to [7], characterized in that the liquid substance with a low taurine solubility is a water-soluble organic solvent, and the taurine solubility of the water-soluble organic solvent is less than 1.0 g / 100 g of liquid substance (25° C.).
[0026] [9] A production method as described in [8], characterized in that the aforementioned water-soluble organic solvent is one or more selected from the group consisting of ethanol, isopropanol, ethylene glycol, 1,2-propylene glycol, 1,3-propylene glycol, 1,2-butylene glycol, 1,3-butylene glycol, isoprene glycol, diethylene glycol, dipropylene glycol, diethylene glycol monoethyl ether, glycerol, diglycerol, triglyceride, 1,2-pentanediol, 1,2-hexanediol, cyclohexylglycerol and N-hexylglycerol.
[0027]
[10] A method for producing a skin external preparation component containing fine needle-shaped or columnar taurine crystals, characterized by comprising the following steps:
[0028] A step of growing crystals in an environment where the taurine aqueous solution is mixed or brought into contact with a liquid substance having a low taurine solubility, and
[0029] A step of incorporating the fine needle-shaped or columnar taurine crystals obtained in the aforementioned crystal growth step into the aforementioned skin external preparation ingredients.
[0030]
[11] The production method as described in
[10] is characterized in that the taurine concentration in the aqueous solution is 3 to 28w%.
[0031]
[12] The production method as described in
[10] or
[11] is characterized in that the ratio of the amount of the liquid substance with low taurine solubility to the total amount of the taurine aqueous solution is less than 50w%.
[0032]
[13] The production method as described in
[10] is characterized in that the liquid substance with low taurine solubility is a water-soluble organic solvent, and the taurine solubility of the water-soluble organic solvent is less than 1.0 g / 100 g of liquid substance (25° C.).
[0033]
[14] A production method as described in
[13] , characterized in that the aforementioned water-soluble organic solvent is one or more selected from the group consisting of ethanol, isopropanol, ethylene glycol, 1,2-propylene glycol, 1,3-propylene glycol, 1,2-butylene glycol, 1,3-butylene glycol, isoprene glycol, diethylene glycol, dipropylene glycol, diethylene glycol monoethyl ether, glycerol, diglycerol, triglyceride, 1,2-pentanediol, 1,2-hexanediol, cyclohexylglycerol and N-hexylglycerol.
[0034]
[15] A manufacturing method as described in
[10] , characterized in that the aforementioned skin external preparation component is a liquid, water-based, emulsion, cream or aqueous gel, and the taurine concentration in the aqueous phase of the mixing step is maintained above the saturation concentration, thereby maintaining fine needle-shaped or columnar taurine crystals in the aforementioned skin external preparation component.
[0035]
[16] A method as described in
[10] , characterized in that the aforementioned skin external preparation component is a flower makeup oil or an ointment, and the fine needle-shaped or columnar taurine crystals obtained in the aforementioned crystal growth step are filtered and dried, and then incorporated into the skin external preparation component in a mixing step.
[0036] Effects of the Invention
[0037] The skin external preparation component of the present invention contains taurine with controlled crystal size and shape, so it does not irritate the skin and has a smooth and delicate touch. Although taurine has a large polarity and low skin permeability, when taurine is converted into fine needle-shaped crystals or columnar crystals and applied to the skin, the needle-shaped crystals enter the stratum corneum of the skin, and the skin permeability of taurine increases, and the drug efficacy is also enhanced. BRIEF DESCRIPTION OF THE DRAWINGS
[0038] [ Figure 1 ] Figure 1 is a microscope photograph showing an example of fine needle-shaped crystals of taurine.
[0039] [ Figure 2 ] Figure 2 is a microscope photograph showing an example of bulk crystals of raw taurine. DETAILED DESCRIPTION
[0040] The skin external preparation component of the present invention is characterized by containing fine needle-shaped or columnar taurine crystals with a thickness of less than 150 microns and a length of less than 3000 microns.
[0041] The fine needle-shaped or columnar taurine crystals of the present invention can be produced by mixing a taurine aqueous solution (A) with a liquid substance (B) with low taurine solubility (e.g., stirring the aqueous solution (A) while adding the liquid substance (B)), or by bringing the taurine aqueous solution (A) into contact with a liquid substance (B) with low taurine solubility (e.g., slowly injecting the liquid substance (B) into the aqueous solution (A) to form an interface), etc., to create a state of extremely low solubility, and allowing taurine to recrystallize (grow crystals) in this state. The obtained fine needle-shaped or columnar taurine crystals have a controlled crystal shape.
[0042] The raw material taurine used in the present invention is not particularly limited, and taurine commonly used in medicines, over-the-counter drugs, and cosmetics can be used, and taurine synthesized or extracted from natural products can also be used.
[0043] The fine needle-shaped or columnar taurine crystals in the present invention are preferably needle-shaped crystals, columnar crystals or a mixture of the two. In this article, needle-shaped crystals refer to crystals with a long diameter greater than or equal to 3 times the short diameter, and columnar crystals refer to crystals with a long diameter less than 3 times the short diameter. The fine needle-shaped or columnar taurine crystals in the present invention and the blocky crystals of the raw material taurine refer to crystal shapes that can be distinguished by microscopic observation. Figure 1 Shows an example of fine needle-shaped crystals, Figure 2 An example of bulk crystallization is shown.
[0044] When fine needle-shaped crystals or columnar crystals of taurine are incorporated into the ingredients of skin external preparations, in order to avoid a rough touch and at the same time impart a dry and refreshing application feel, the size range of the crystals should preferably be 5 to 150 microns in thickness and 100 to 3000 microns in length, more preferably 10 to 100 microns in thickness and 100 to 2000 microns in length, and most preferably 10 to 60 microns in thickness and 150 to 2000 microns in length.
[0045] In this article, thickness refers to the short diameter of the crystal, and length refers to the long diameter of the crystal.
[0046] Crystals with a diameter exceeding 150 microns and a length exceeding 3000 microns (such as taurine crystals and taurine crystalline powder commercially available as raw materials) will feel rough and foreign when applied to the skin, and therefore should not be used.
[0047] In the present invention, although the taurine fine crystals may contain micro-particle crystals with a diameter less than 5 microns and a length less than 100 microns, it is preferred not to contain crystals with a diameter exceeding 150 microns. According to the method for producing taurine fine needle-shaped crystals or columnar crystals of the present invention, the recrystallization conditions may be set to avoid the formation of needle-shaped crystals or columnar crystals with a diameter exceeding 150 microns.
[0048] The specific recrystallization (crystal growth) condition is to allow crystals to grow in an environment where the taurine aqueous solution (A) is mixed or in contact with a liquid substance (B) with a low taurine solubility.
[0049] The liquid substance (B) with low taurine solubility used for recrystallization (crystal growth) may include organic solvents, but are not limited thereto, such as polar organic solvents such as acetone, methyl ethyl ketone, dimethyl sulfoxide, dimethylformamide, ethyl acetate, isopropyl myristate, methyl heptyl laurate and jojoba oil; non-polar organic solvents such as dodecane, isododecane, liquid paraffin, squalane, hydrogenated polyisobutylene and olefin oligomers; alcohols such as ethanol and 1-propanol; polyols such as 1,3-butanediol, glycerol, 1,2-pentanediol, etc. Among them, since the effect of reducing the solubility of taurine after addition is better, the liquid substance (B) is preferably a liquid substance (water-soluble organic solvent) with a solubility of 1w% or more in water at 25°C, and more preferably a water-soluble organic solvent with a taurine solubility of 1.0g / 100g (25°C) or less. Specifically, the liquid substance (B) is preferably selected from the group consisting of ethanol, 1-propanol, 2-propanol, 1-butanol, 2-butanol, ethylene glycol, diethylene glycol, 1,2-propylene glycol, 1,3-propylene glycol, 1,2-butylene glycol, 1,3-butylene glycol, isoprene glycol, dipropylene glycol, diethylene glycol monoethyl ether, glycerol, diglycerol, triglyceride, 1,2-pentanediol, 1,2-hexanediol, acetone, methyl ethyl ketone, dimethyl sulfoxide, dimethylformamide, cyclohexylglycerol and n-hexylglycerol. One or more selected solvents are preferably selected from the group consisting of ethanol, isopropanol, ethylene glycol, 1,2-propylene glycol, 1,3-propylene glycol, 1,2-butylene glycol, 1,3-butylene glycol, isopentyl glycol, diethylene glycol, dipropylene glycol, diethylene glycol monoethyl ether, glycerol, diglycerol, triglyceride, 1,2-pentanediol, 1,2-hexanediol, cyclohexylglycerol and n-hexylglycerol, from the viewpoint that the obtained fine needle-shaped crystals are used as a component of a skin external preparation. When two or more selected solvents are selected, they may be used as a mixed solvent.
[0050] If a liquid substance (B) with low taurine solubility is not used, the crystal shape will not become fine needle-like or columnar crystals, and when incorporated into the ingredients of skin external preparations, it will give a rough feeling during use, so it is not suitable for use.
[0051] In order to allow taurine to form fine needle-shaped crystals when mixed with a solvent with a low taurine solubility, the taurine concentration in the taurine aqueous solution (A) used for recrystallization is preferably 3w% or more, and from the viewpoint of the solubility of taurine in water, it is preferably 28w% or less. If the taurine concentration is lower than 3w%, as long as the ratio of the added liquid substance (B) to the aqueous solution (A) is lower than 100w%, crystals will not precipitate, and sufficient crystals cannot be obtained, so it is not realistic in terms of cost and yield. If the taurine concentration exceeds 28w%, it is difficult to dissolve taurine even if it is heated to above 80°C, so the recrystallization process is not realistic. In view of this, the taurine concentration in the aqueous solution (A) is usually 5-20w%, preferably 6-18w%, and preferably 7-15w%.
[0052] In order to reduce the saturation concentration, one or more water-soluble organic solvents with low taurine solubility can be added to the taurine aqueous solution (A) used for recrystallization. The water-soluble organic solvent at this time is preferably glycerol, 1,3-propylene glycol, ethanol, isopropanol, ethylene glycol, 1,2-propylene glycol, 1,2-butylene glycol, 1,3-butylene glycol, isopentyl glycol, diethylene glycol, dipropylene glycol, diethylene glycol monoethyl ether, diglycerol, triglyceride, 1,2-pentanediol, 1,2-hexanediol, cyclohexylglycerol, N-hexylglycerol, etc. The concentration of the above-mentioned water-soluble organic solvent in the taurine aqueous solution (A) is usually less than 50w%, preferably less than 30w%, and preferably less than 25w%. If the concentration of the above-mentioned water-soluble organic solvent exceeds 50w%, the taurine solubility will be too low, and sufficient crystallization amount cannot be obtained, which is unrealistic in terms of cost and yield.
[0053] The fine needle-shaped or columnar taurine crystals obtained by the present invention can be incorporated into skin external preparations after filtering and drying, or the solution from which the fine needle-shaped or columnar crystals are precipitated can be directly incorporated into skin external preparations.
[0054] The skin external preparation component of the present invention can be mainly used as an external component of flower cosmetics and over-the-counter drugs. The dosage form of the component of the present invention is not particularly limited, and examples thereof include liquid, water, flower cosmetic oil, emulsion, cream, aqueous gel, ointment, etc. These preparations can be prepared by common methods.
[0055] Regarding liquid preparations, water preparations, emulsions, creams, and aqueous gels, the taurine concentration in the aqueous phase can be maintained at or above the saturation concentration, and the preparations can be prepared while maintaining fine needle-shaped or columnar crystals.
[0056] For flower makeup oils and ointments, the preparations can be prepared by incorporating the filtered and dried fine needle-shaped crystals.
[0057] Furthermore, within the scope that does not affect the effect of the present invention, the components of the skin external preparation of the present invention may also contain components commonly used in preparations such as flower cosmetics, over-the-counter drugs, and external medicines. In this specification, these components are referred to as useful substances. The components of the skin external preparation of the present invention preferably contain useful substances. As for useful substances, water, oils, surfactants, gelling agents, powders, alcohols, water-soluble polymers, film-forming agents, resins, UV-blocking agents, inclusion compounds, antibacterial agents, fragrances, deodorants, salts, pH adjusters, detergents, etc. can be listed. agents, animal and microbial extracts, plant extracts, blood circulation promoters, astringents, anti-seborrhea agents, whitening agents, anti-inflammatory agents, moisturizers, keratolytic agents, enzymes, hormones and vitamins, etc. One or more useful substances can be used.
[0058] The water contained in the components of the external skin preparation of the present invention is not particularly limited, and examples thereof include distilled water, deionized water, and tap water.
[0059] As the water-soluble alcohol, there can be mentioned lower alcohols, polyols, polymer polyols, diol ethers, diol ether esters, glycerol monoalkyl ethers, sugar alcohols, monosaccharides, oligosaccharides, polysaccharides and derivatives thereof.
[0060] Examples of the lower alcohol include ethanol, propanol, isopropanol, isobutanol, and tert-butanol.
[0061] Examples of the polyol include diols (e.g., dipropylene glycol, 1,3-butylene glycol, ethylene glycol, 1,3-propanediol, 1,2-butylene glycol, 1,4-butylene glycol, 2,3-butylene glycol, 1,5-pentanediol, 1,4-butene glycol, hexanediol, octanediol, etc.), triols (e.g., glycerol, trimethylolpropane, etc.), tetraols (e.g., diglycerol, 1,2,6-hexanetriol and other pentaerythritol, etc.), pentaols (e.g., xylitol, triglycerides, etc.), hexaols (e.g., sorbitol, mannitol, etc.), polyol polymers (e.g., diethylene glycol, etc.), and polyols such as propylene glycol. , dipropylene glycol-triethylene glycol, polyethylene glycol, tetraethylene glycol, diglycerol-triglyceride, tetraglycerol, polyglycerol, etc.), dialkyl alcohol ethers (for example, ethylene glycol monomethyl ether, ethylene glycol monoethyl ether, ethylene glycol monobutyl ether, ethylene glycol monophenyl ether, ethylene glycol monohexyl ether, ethylene glycol mono-2-ethylhexyl ether, ethylene glycol isoamyl ether, ethylene glycol benzyl ether, ethylene glycol isopropyl ether, ethylene glycol dimethyl ether, ethylene glycol diethyl ether, ethylene glycol dibutyl ether, etc.), dialkyl alcohol ethers (for example, diethylene glycol monomethyl ether, diethylene glycol monoethyl ether, diethylene glycol monobutyl ether, diethylene glycol dimethyl ether, diethylene glycol diethyl ether, diethylene glycol dibutyl ether, diethylene glycol methyl ethyl ether, triethylene glycol monomethyl ether, triethylene glycol monoethyl ether, propylene glycol monomethyl ether, propylene glycol monoethyl ether, propylene glycol monobutyl ether, propylene glycol isopropyl ether, dipropylene glycol methyl ether, dipropylene glycol ethyl ether, dipropylene glycol butyl ether, etc.), glycol ether esters (for example, ethylene glycol monomethyl ether acetate, ethylene glycol monoethyl ether acetate, ethylene glycol monobutyl ether acetate, ethylene glycol monophenyl ether acetate, ethylene glycol diadipic acid ester, ethylene glycol disuccinate, diethylene glycol monoethyl ether acetate, diethylene glycol monobutyl ether acetate, propylene glycol monomethyl ether acetate, propylene glycol monoethyl ether acetate esters, propylene glycol monopropyl ether acetate, propylene glycol monophenyl ether acetate, etc.), glycerol monoalkyl ethers (for example, hexanol, squalane alcohol, batyl alcohol, etc.), sugar alcohols (for example, maltotriose, mannitol, sucrose, erythritol, glucose, fructose, starch hydrolyzed sugar, maltose, starch hydrolyzed sugar reducing alcohol, etc.), Glysolid, tetrahydrofurfuryl alcohol, POE-tetrahydrofurfuryl alcohol, POP-butyl ether, POP·POE-butyl ether, tripolyoxypropylene glycerol ether, POP-glycerol ether, POP-glycerol ether phosphoric acid, POP·POE-pentaneerythritol ether, polyglycerol, etc.
[0062] Examples of monosaccharides include trisaccharides (e.g., D-glyceraldehyde, dihydroxyacetone, etc.), tetrasaccharides (e.g., D-erythrose, D-erythrulose, D-threose, erythritol, etc.), pentoses (e.g., L-arabinose, D-xylose, L-lyxose, D-arabinose, D-ribose, D-ribulose, D-xylose, L-xylose, etc.), hexoses (e.g., D-glucose, D-talose, D-psicose, D-galactose, D-fructose, L-galactose, L-mannose, D-tagatose, etc.), heptose (e.g., aldoheptose, heptulose, etc.), octose (e.g., octulose, etc.), deoxy sugars (e.g., 2-deoxy-D-ribose, 6-deoxy-L-galactose, 6-deoxy-L-mannose, etc.), amino sugars (e.g., D-glucosamine, D-galactosamine, sialic acid, aminouronic acid, muramic acid, etc.), uronic acids (e.g., D-glucuronic acid, D-mannuronic acid, L-guluronic acid, D-galacturonic acid, L-iduronic acid, etc.), etc.
[0063] As oligosaccharides, sucrose, gentiotriose, umbelliferyl, lactose, plantaginose, isolysaccharides, α,α-trehalose, raffinose, lysin, umbilicin, stachyose, verbascose and the like can be cited.
[0064] Examples of the polysaccharide include cellulose, quince seeds, starch, galactan, dermatan sulfate, glycogen, gum arabic, heparan sulfate-tragacanth, keratan sulfate, chondroitin, xanthan gum, guar gum, dextran, keratan sulfate, locust bean gum, and succinoglucan.
[0065] Examples of the anti-inflammatory agent include plant extracts, allantoin and its derivatives, glycyrrhetinic acid and its derivatives, glycyrrhizic acid and its salts or derivatives, salicylic acid derivatives, aminocaproic acid, azulene and its derivatives.
[0066] As for the gelling agent (thickener), gum arabic, carrageenan, karaya gum, tragacanth gum, carob gum, quince seed (quince coffin), casein, dextrin, gelatin, sodium pectate, sodium alginate, methylcellulose, ethyl cellulose, CMC, hydroxyethyl cellulose, hydroxypropyl cellulose, PVA, PVM, PVP, sodium polyacrylate, carboxyvinyl polymer, locust bean gum, guar gum, tamarind seed gum, dialkyldimethylammonium cellulose sulfate, xanthan gum, magnesium aluminum silicate, bentonite, hectorite, magnesium aluminum silicate (VEEGUM), laponite, anhydrous silicic acid, etc. can be listed.
[0067] Regarding natural water-soluble polymers, there can be listed plant-based polymers (for example, gum arabic, tragacanth gum, galactan, guar gum, carob gum, karaya gum, carrageenan, pectin, agar, quince seeds (quince), alginate (brown algae extract), starch (rice, corn, potato, wheat), glycyrrhizic acid), microbial-based polymers (for example, xanthan gum, dextran, succinoglucan, pullulan, etc.), animal-based polymers (for example, collagen, casein, albumin, gelatin, etc.), etc.
[0068] Regarding semi-synthetic water-soluble polymers, there can be listed starch-based polymers (for example, carboxymethyl starch, methyl hydroxypropyl starch, etc.), cellulose-based polymers (methyl cellulose, ethyl cellulose, methyl hydroxypropyl cellulose, hydroxyethyl cellulose, sodium cellulose sulfate, hydroxypropyl cellulose, carboxymethyl cellulose, sodium carboxymethyl cellulose, crystalline cellulose, cellulose powder, etc.), alginate-based polymers (for example, sodium alginate, propylene glycol alginate, etc.), etc.
[0069] Regarding synthetic water-soluble polymers, there can be listed vinyl polymers (for example, polyvinyl alcohol, polyvinyl methyl ether, polyvinyl pyrrolidone, carboxyvinyl polymers, etc.), polyoxyethylene polymers (for example, polyethylene glycol 20,000, 40,000, 60,000, etc.), acrylic polymers (for example, sodium polyacrylate, polyethyl acrylate, polyacrylamide, etc.), polyethylene imine, cationic polymers, etc.
[0070] As moisturizers, chondroitin sulfate, hyaluronic acid, mucopolysaccharide sulfate, charonin sulfate, atelocollagen, cholesterol-12-hydroxystearate, sodium lactate, bile acid salts, DL-pyrrolidone carboxylate, short-chain soluble collagen, diglycerol (EO) PO additives, silk flower extract, yarrow extract, and sweet osmanthus extract can be listed.
[0071] Regarding whitening agents (whitening ingredients), there can be listed tranexamic acid, ascorbic acid and its salts, ascorbic acid derivatives such as vitamin C (sodium ascorbyl phosphate, magnesium ascorbyl phosphate, ascorbic acid tetra-2-hexyldecanoate, 2-o-ethyl ascorbic acid, 3-o-ethyl ascorbic acid, ascorbyl glucoside, etc.), arbutin, kojic acid, placenta, ellagic acid, niacinamide, hydroquinone, linoleic acid and its derivatives, etc.
[0072] Examples of keratolytic agents (keratin softening ingredients) include lactic acid, salicylic acid, gluconic acid, glycolic acid, citric acid, malic acid, α-hydroxy acid, phytic acid, urea, sulfur, and the like.
[0073] As anti-aging ingredients, hydrolyzed soy protein, retinoids (retinol and its derivatives, retinoic acid and retinal, etc.), kinetin, adenosine, NMN (nicotinamide mononucleotide), AMP (adenosine monophosphate), ADP (adenosine diphosphate), ATP (adenosine triphosphate), ursolic acid, turmeric extract, sphingosine derivatives, mevalonolactone, etc. are listed.
[0074] Examples of anti-glycation ingredients include plant extracts such as Buddleja axillaris leaf extract, evening primrose oil, emblica fruit and juice or extracts thereof, L-arginine, L-lysine, hydrolyzed casein, hydrolyzed tannin, and carnosine.
[0075] Regarding blood circulation promoters (ingredients with blood circulation promoting effects), there can be listed Korean ginseng, ashitaba, arnica, ginkgo, fennel, hairy-leaved balsam pear, Dutch oak, chamomile, Roman chamomile, carrot, yellow gentian, burdock, rice, hawthorn, shiitake mushroom, ginger, single-fruited hawthorn, European juniper, Japanese chuanxiong, Japanese swertia, thyme, clove, tangerine peel, pepper, oriental angelica, peach kernel, fish-scale spruce, carrot, garlic, butcher's leaf, grape, peony, European horse chestnut, lemon balm, grapefruit, coix seed, green tea, rosemary, rose hip, peach, apricot, walnut, corn, golden chamomile, ichthyol, blister beetle tincture, cephalothin, etc.; plant-derived ingredients such as γ-oryzanol, nicotinic acid tocopherol, glucosyl hesperidin, etc.
[0076] Examples of the polyphenols include flavonoid polyphenols such as curcumin, flavanones, stilbenoids, polymethoxyflavones, flavonols, xanthones, chalcones, phenylpropanoids, flavanols, and isoflavones.
[0077] As metal ion chelating agents, there can be mentioned 1-hydroxyethane-1,1-diphosphoric acid, tetrasodium 1-hydroxyethane-1,1-diphosphoric acid, disodium edetate, trisodium edetate, tetrasodium edetate, sodium citrate, sodium polyphosphate, sodium metaphosphate, gluconic acid, phosphoric acid, citric acid, ascorbic acid, succinic acid, edetic acid, trisodium hydroxyethylethylenediaminetriacetic acid, and the like.
[0078] As for the UV blocking agent (water-soluble UV absorber), there can be mentioned 2,4-dihydroxybenzophenone, 2,2'-dihydroxy-4-methoxybenzophenone, 2,2'-dihydroxy-4,4'-dimethoxybenzophenone, 2,2',4,4'-tetrahydroxybenzophenone, 2-hydroxy-4-methoxybenzophenone, 2-hydroxy-4-methoxy-4'-methylbenzophenone, 2-hydroxy-4-methoxy-5-sulfonic acid benzophenone, 4-phenylbenzophenone, Benzophenone type ultraviolet absorbers such as benzophenone, 2-ethylhexyl-4'-phenylbenzophenone-2-carboxylate, 2-hydroxy-4-n-octyloxybenzophenone, 4-hydroxy-3-carboxybenzophenone, phenylbenzimidazole-5-sulfonic acid and its salts, phenylene-bis-benzimidazole-tetrasulfonic acid and its salts, benzimidazole type ultraviolet absorbers such as 3-(4-methylbenzylidene)-d, L-camphor, 3-benzylidene-d, L-camphor, urocanic acid, ethyl urocanate, etc.
[0079] As for the powder (powder component), inorganic powder (for example, talc, kaolin, mica, sericite, muscovite, phlogopite, synthetic mica, red mica, biotite, vermiculite, magnesium carbonate, calcium carbonate, aluminum silicate, barium silicate, calcium silicate, magnesium silicate, strontium silicate, metal tungstate, magnesium, silicon dioxide, zeolite, barium sulfate, calcined calcium sulfate (calcined gypsum), calcium phosphate, fluoroapatite, hydroxyapatite, ceramic powder, metal soap (for example, zinc myristate, calcium palmitate, aluminum stearate), boron nitride, etc.), organic powder (for example, polyamide resin powder powder (nylon powder), polyethylene powder, polymethyl methacrylate powder, polystyrene powder, styrene and acrylic acid copolymer resin powder, benzoguanamine resin powder, polytetrafluoroethylene powder, cellulose powder, etc.), inorganic white pigments (e.g., titanium dioxide, zinc oxide, etc.), inorganic red pigments (e.g., iron oxide (ferric oxide), ferrous titanate, etc.), inorganic brown pigments (e.g., γ-iron oxide, etc.), inorganic yellow pigments (e.g., yellow iron oxide, loess, etc.), inorganic black pigments (e.g., black iron oxide, titanium, etc.), inorganic purple pigments (e.g., manganese violet, cobalt violet, etc.), inorganic green pigments (e.g., chromium oxide, chromium hydroxide, titanium cobalt oxide, etc.), inorganic blue pigments (e.g., ultramarine, dark blue, etc.), pearlescent pigments (e.g., titanium dioxide coated mica, titanium dioxide coated bismuth oxychloride, titanium dioxide coated talc, colored titanium dioxide coated mica, bismuth oxychloride, fish scale foil, etc.), metal powder pigments (e.g., aluminum powder, copper powder, etc.), organic pigments such as zirconium, barium or aluminum lakes (e.g., Red 201, Red 202, Red 204, Red 205, etc.), organic pigments such as Red No. 205, Red No. 220, Red No. 226, Red No. 228, Red No. 405, Orange No. 203, Orange No. 204, Yellow No. 205, Yellow No. 401, and Blue No. 404, Red No. 3, Red No. 104, Red No. 106, Red No. 227, Red No. 230, Red No. 401, Red No. 505, Orange No. 205, Yellow No. 4, Yellow No. 5, Yellow No. 202, Yellow No. 203, Green No. 3, and Blue No. 1, etc.), natural pigments (for example, chlorophyll, β-carotene, etc.), etc.
[0080] As vitamins, there can be mentioned vitamins A, B1, B2, B6, C, E and their derivatives, pantothenic acid and its derivatives, biotin and the like.
[0081] Regarding amino acids, there can be listed neutral amino acids (glycine, alanine, valine, leucine, isoleucine), aliphatic amino acids, hydroxy amino acids (serine, threonine), aliphatic amino acids, sulfur-containing amino acids (cysteine, cystine, methionine), acidic amino acids (glutamine, asparagine), basic amino acids (arginine), aromatic amino acids (phenylalanine, tyrosine), and cyclic amino acids (proline, hydroxyproline).
[0082] As peptides, human oligopeptides, tripeptides, acetyl hexapeptides, palmitoyl pentapeptides, collagen peptides and the like can be cited.
[0083] As the antioxidant, tocopherols, butylated hydroxytoluene, butylated hydroxyanisole, gallic acid esters and the like are exemplified.
[0084] Examples of the pH adjuster include buffers such as lactic acid-sodium lactate, citric acid-sodium citrate, and succinic acid-sodium succinate.
[0085] As oils (oil phase components), liquid oils, solid oils, waxes, hydrocarbon oils, higher fatty acids, synthetic ester oils, silicone oils, etc. commonly used in cosmetics and over-the-counter drugs can be cited. These oil phase components and the above-mentioned water phase components can be combined with appropriate surfactants to form skin components.
[0086] As for liquid oils and fats, there can be listed avocado oil, camellia oil, turtle oil, macadamia oil, corn oil, mink oil, olive oil, rapeseed oil, egg yolk oil, sesame oil, peach almond oil, wheat germ oil, camellia oil, castor seed oil, linseed oil, safflower oil, cottonseed oil, perilla oil, soybean oil, peanut oil, tea seed oil, torreya seed oil, rice bran oil, tung oil, Japanese tung oil, jojoba oil, germ oil, triglycerides, etc.
[0087] Examples of solid fats and oils include cocoa butter, coconut oil, horse fat, hardened coconut oil, palm oil, beef tallow, mutton tallow, hardened beef tallow, palm kernel oil, lard, beef bone fat, wood wax kernel oil, hardened oil, tallow, wood wax, and hardened castor oil.
[0088] As for waxes, beeswax, candelilla wax, cotton wax, carnauba wax, bayberry wax, white wax, spermaceti, montan wax, rice bran wax, lanolin, Java cottonseed wax, acetylated lanolin, lanolin oil, sugarcane (SACCHARUM OFFICINARUM) wax, isopropyl lanolin acid, hexyl laurate, hydrogenated lanolin, jojoba wax, hard lanolin, shellac wax, polyoxyethylene lanolin alcohol ether, polyoxyethylene lanolin ethanol acetate, polyoxyethylene cholesteryl ethyl ether, PEG-20 lanolin acid ester, polyoxyethylene hydrogenated lanolin alcohol ether, cetyl palmitate, etc. can be listed.
[0089] Examples of the hydrocarbon oil include liquid paraffin, ozokerite, squalane, pristane, paraffin, ceresin, squalene, vaseline, and microcrystalline wax.
[0090] Examples of higher fatty acids include lauric acid, myristic acid, palmitic acid, stearic acid, behenic acid, oleic acid, undecylenic acid, tall oil acid, linoleic acid, linolenic acid, eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA).
[0091] As the synthetic ester oil, there can be mentioned cetyl octanoate, myristyl myristate, glyceryl tri-2-ethylhexanoate, pentaerythritol tetra(2-ethylhexanoate), dioctyl succinate, tripropylene glycol dipivalate, and the like.
[0092] Regarding silicone oil, there can be listed chain polysiloxanes (for example, dimethyl polysiloxane, methylphenyl polysiloxane, diphenyl polysiloxane, etc.); cyclic polysiloxanes (for example, octamethylcyclotetrasiloxane, decamethylcyclopentasiloxane, dodecamethylcyclohexasiloxane, etc.), silicone resins forming a three-dimensional grid structure, silicone rubber, various modified polysiloxanes (amino-modified polysiloxane, polyether-modified polysiloxane, alkyl-modified polysiloxane, fluorine-modified polysiloxane, etc.), acrylic silicons, etc. DETAILED DESCRIPTION
[0094] The present invention is described in detail below by way of examples, comparative examples, and test examples, but the embodiments of the present invention are not limited thereto.
[0095] Unless otherwise specified, the mixing amount hereinafter is w%, and the unit of thickness and length is micrometer.
[0096] Comparative Example 1
[0097] Commercially available natural taurine (product name: Taurine (extract), manufactured by Chori Co., Ltd.) was used.
[0098] Comparative Example 2
[0099] Commercially available synthetic taurine (product name: Japanese Pharmacopoeia Taurine, manufactured by Xiaohua Pharmaceutical Co., Ltd.) was used.
[0100] Comparative Example 3
[0101] A 10% taurine aqueous solution was heated to 50°C to uniformly dissolve the taurine solution, then cooled to room temperature and allowed to stand for 24 hours. The precipitated crystals were separated by filtration and dried to obtain a crystal.
[0102] Example 1
[0103] An aqueous solution containing 10% taurine and 10% 1,3-propylene glycol was heated to 50° C. to uniformly dissolve the mixture, and then cooled to 30° C. while stirring with a disperser. The precipitated crystals were separated by filtration, washed with ethanol, and dried to obtain crystals.
[0104] Example 2
[0105] After heating a 10% taurine aqueous solution to 50°C for uniform dissolution, the solution was cooled to 30°C while stirring, and ethanol in a proportion of 10% of the total taurine solution was added while stirring. The precipitated crystals were separated by filtration, washed with ethanol, and dried to obtain crystals.
[0106] Example 3
[0107] After heating a 10% taurine aqueous solution to 50°C for uniform dissolution, the solution was cooled to 30°C while stirring, and 1,3-butanediol was added at a ratio of 10% of the total amount of the taurine solution while stirring. The precipitated crystals were separated by filtration, washed with ethanol, and dried to obtain crystals.
[0108] Example 4
[0109] After heating a 10% taurine and 10% glycerol aqueous solution to 50°C for uniform dissolution, the solution was cooled to 30°C while stirring, and ethanol in a proportion of 10% of the total taurine solution was added while stirring. The precipitated crystals were separated by filtration, washed with ethanol, and dried to obtain crystals.
[0110] Example 5
[0111] After heating a 10% taurine aqueous solution to 50°C for uniform dissolution, the solution was cooled to 30°C while stirring, and then slowly injected with ethanol in a ratio of 10% of the total amount of the taurine solution. At the interface of the solid-liquid phase, the precipitated crystals were filtered and separated, washed with ethanol, and dried to obtain crystals.
[0112] Example 6
[0113] After heating a 10% taurine aqueous solution to 50°C for uniform dissolution, the solution was cooled to 30°C while stirring, and then poured into ethanol with a ratio of 10% of the total amount of the taurine solution while stirring. The precipitated crystals were separated by filtration, washed with ethanol, and dried to obtain crystals.
[0114] Example 7
[0115] After heating a 10% taurine and 10% glycerol aqueous solution to 50°C for uniform dissolution, the solution was cooled to 30°C while stirring, and then poured into ethanol with a ratio of 10% of the total amount of the taurine solution while stirring. The precipitated crystals were separated by filtration, washed with ethanol, and dried to obtain crystals.
[0116] Example 8
[0117] After heating a 10% taurine and 10% glycerol aqueous solution to 50°C for uniform dissolution, the solution was cooled to 30°C while stirring, and then injected into 1,3-propylene glycol in a ratio of 10% of the total amount of the taurine solution while stirring. The precipitated crystals were separated by filtration, washed with ethanol, and dried to obtain crystals.
[0118] Example 9
[0119] After heating a 10% taurine and 10% glycerol aqueous solution to 50°C for uniform dissolution, the solution was cooled to 30°C while stirring, and then injected into 1,2-pentanediol at a ratio of 3% of the total amount of the taurine solution while stirring. The precipitated crystals were separated by filtration, washed with ethanol, and dried to obtain crystals.
[0120] Example 10
[0121] The 18% taurine aqueous solution was heated to 65°C to make it uniformly dissolved, and then the solution was poured into 1,3-propylene glycol (10% of the total amount of the taurine solution) while stirring. The precipitated crystals were separated by filtration, washed with ethanol and dried to obtain crystals.
[0122] Embodiment 11
[0123] The 18% taurine aqueous solution was heated to 65°C to make it uniformly dissolved, and then the solution was injected into a mixed solution of 1,3-propylene glycol and 5% diethylene glycol monomethyl ether in a ratio of 5% to the total amount of the taurine solution while stirring. The precipitated crystals were separated by filtration, washed with ethanol, and dried to obtain crystals.
[0124] Test Example 1
[0125] The crystals of Comparative Examples 1 to 3 and the crystals obtained in Examples 1 to 11 were observed under a microscope. Tables 4 to 6 show the crystal shape, crystal thickness, and crystal length.
[0126] Production Example 1
[0127] The crystals of Comparative Examples 1 to 3 and the crystals obtained in Examples 1 to 11 were blended into the emulsion formulations shown in Table 1 to prepare emulsions.
[0128] In addition, the taurine concentration in phase A was set to a saturated concentration at 25°C, phase B was added to phase A heated to 80°C while mixing with a homogenizer, phase C was mixed after cooling to 25°C, and the taurine crystals of layer D were mixed with the obtained components to prepare an emulsion containing crystals.
[0129] Production Example 2
[0130] The crystals of Comparative Examples 1 to 3 and the crystals obtained in Examples 1 to 11 were blended into the flower makeup oil formulations shown in Table 2 to prepare flower makeup oils.
[0131] Separately, phase A was heated to 100°C and mixed uniformly, then cooled to 25°C, and the taurine crystals of phase B were mixed therein to prepare a flower makeup oil containing the crystals.
[0132] [Table 1]
[0133]
[0134]
[0135] [Table 2]
[0136]
[0137] The inventors conducted a sensory evaluation on the use feeling of the prepared emulsion and floral oil with 5 participants. The inventors evaluated each item according to the criteria shown in Table 3, and the average score was used as the score. The results are shown in Tables 4 to 6.
[0138] [Table 3]
[0139] 0 points There is always a strong rough feeling 2 points There is always a slight rough feeling 4 points Often have a weak rough feeling 6 points Occasionally there is a slight rough feeling 8 points A dry touch 10 points Very dry feeling
[0140] [Table 4]
[0141]
[0142]
[0143] [Table 5]
[0144]
[0145] [Table 6]
[0146]
[0147] As shown in Tables 4 to 6, the taurine crystals obtained by the production method of the present invention can control the crystal size, so that the roughness is not seen in the use feeling of the mixed product, and the use feeling is significantly improved.
[0148] The following are examples of formulations, but the embodiments of the present invention are not limited thereto.
[0149] lotion
[0150] 〔A〕
[0151]
[0152]
[0153] 〔B〕
[0154] Dipropylene glycol 10.00w%
[0155] 1,2-Pentanediol 2.50w%
[0156] 〔C〕
[0157] Acrylates / stearyl alcohol polyether-20 methacrylate copolymer 0.45w%
[0158] Distilled water 1.05w%
[0159] Phase A, which was heated to 80°C and uniformly dissolved, was cooled to 35°C and added to phase B while stirring. It was stirred at 35°C for 10 minutes to precipitate fine needle-shaped crystals of taurine. Phase C was added thereto and stirred for 10 minutes with a homogenizer to uniformly mix, thereby obtaining an emulsion component.
[0160] The obtained component had a needle-like shape of taurine fine crystals with a maximum thickness of 50 micrometers and a maximum length of 750 micrometers. The obtained component had a smooth and delicate feel during use, thus obtaining an ingredient with a good feel during use.
[0161] Aqueous gel
[0162] 〔A〕
[0163]
[0164] 〔B〕
[0165] Dipropylene glycol 10.00w%
[0166] 1,2-Pentanediol 2.50w%
[0167] 〔C〕
[0168] Polyacrylate Crosspolymer-6 2.00w%
[0169] Phase A, which was heated to 80°C and uniformly dissolved, was cooled to 35°C and added to phase B while stirring. It was stirred at 35°C for 10 minutes to precipitate fine needle-shaped crystals of taurine. Phase C was added thereto and stirred for 10 minutes with a homogenizer to uniformly mix, thereby obtaining an emulsion component.
[0170] The obtained component had a needle-like shape of taurine fine crystals with a maximum thickness of 50 micrometers and a maximum length of 750 micrometers. The obtained component had a smooth and delicate feel during use, thus obtaining an ingredient with a good feel during use.
[0171] Lotion
[0172] 〔A〕
[0173] Distilled water 63.20w%
[0174] Taurine 8.00w%
[0175] Glycerin 5.00w%
[0176] 〔B〕
[0177] Propylene glycol 15.00w%
[0178] 1,2-Pentanediol 1.50w%
[0179] Phenoxyethanol 0.30w%
[0180] 〔C〕
[0181]
[0182] 〔D〕
[0183] Squalane 5.00w%
[0184] Phase A, which was heated to 80°C and dissolved uniformly, was cooled to 35°C and added to phase B while stirring. The mixture was stirred at 35°C for 10 minutes to precipitate fine needle-shaped crystals of taurine. Phase C was added thereto and stirred uniformly for 5 minutes with a homogenizer. Phase D was then added and stirred for 10 minutes with a homogenizer to emulsify the mixture, thereby obtaining an emulsion component.
[0185] The obtained component had a needle-like shape of taurine fine crystals with a maximum thickness of 30 micrometers and a maximum length of 250 micrometers. The obtained component had a smooth and delicate feel during use, thus obtaining an ingredient with a good feel during use.
[0186] Cream
[0187] 〔A〕
[0188] Distilled water 68.00w%
[0189] Taurine 8.00w%
[0190] Glycerin 5.00w%
[0191] 〔B〕
[0192] 1,3-Propanediol 15.00w%
[0193] 1,2-Pentanediol 1.50w%
[0194] Phenoxyethanol 0.30w%
[0195] 〔C〕
[0196] Hydroxyethyl acrylate / sodium acryloyldimethyl taurate copolymer 0.75w%
[0197] Polysorbate 80 0.15w%
[0198] Distilled water 0.65w%
[0199] 〔D〕
[0200] Squalane 0.65w%
[0201] Phase A, which was heated to 80°C and dissolved uniformly, was cooled to 35°C and added to phase B while stirring. The mixture was stirred at 35°C for 10 minutes to precipitate fine needle-shaped crystals of taurine. Phase C was added thereto and stirred uniformly for 5 minutes with a homogenizer. Phase D was then added and stirred for 10 minutes with a homogenizer to emulsify the mixture, thereby obtaining an emulsion component.
[0202] The obtained component had a needle-like shape of taurine fine crystals with a maximum thickness of 30 micrometers and a maximum length of 250 micrometers. The obtained component had a smooth and delicate feel during use, thus obtaining an ingredient with a good feel during use.
[0203] W / O type cream
[0204] 〔A〕
[0205] Distilled water 34.30w%
[0206] Taurine 7.00w%
[0207] Glycerin 5.00w%
[0208] 〔B〕
[0209] 1,3-Propanediol 9.00w%
[0210] 1,2-Hexanediol 0.70w%
[0211] Phenoxyethanol 0.30w%
[0212] 〔C〕
[0213]
[0214] Phase A, which was heated to 80°C and dissolved uniformly, was cooled to 35°C and added to phase B while stirring. The mixture was stirred at 35°C for 10 minutes to precipitate fine needle-shaped crystals of taurine. The mixture was added to the uniformly mixed phase C while stirring with a homogenizer for 5 minutes, and then stirred with a homogenizer for 10 minutes to emulsify and obtain a W / O type cream component.
[0215] The obtained component had a needle-like shape of taurine fine crystals with a maximum thickness of 25 micrometers and a maximum length of 200 micrometers. The obtained component had a smooth and delicate feel during use, thus obtaining an ingredient with a good feel during use.
[0216] Pile oil
[0217] 〔A〕
[0218]
[0219] 〔B〕
[0220] The taurine fine needle crystals obtained in Example 5 were 0.50w%
[0221] Phase A was heated to 100°C and stirred until uniform. After cooling to 35°C, phase B was added and stirred to be uniformly dispersed to obtain a flower makeup oil component.
[0222] The obtained component had a needle-like shape of taurine fine crystals with a maximum thickness of 55 micrometers and a maximum length of 800 micrometers. The obtained component had a smooth and delicate feel during use, thus obtaining an ingredient with a good feel during use.
[0223] Taking needle-shaped crystals (Example) and block-shaped crystals (Comparative Example) as representative examples, Figure 1 and Figure 2 Displayed in.
Claims
1. A component of a skin external preparation, It is characterized in that Contains fine needle-shaped or columnar taurine crystals with a thickness of less than 150 microns and a length of less than 3000 microns.
2. The skin external preparation ingredient according to claim 1, Its characteristics are also Contains useful substances.
3. The skin external preparation ingredient according to claim 1 or 2, It is characterized in that The aforementioned fine needle-shaped or columnar taurine crystals grow in an environment where a taurine aqueous solution is mixed or brought into contact with a liquid substance having a low taurine solubility.
4. The skin external preparation ingredient according to claim 3, It is characterized in that The aforementioned liquid substance with low taurine solubility is a water-soluble organic solvent.
5. A method for producing fine needle-shaped or columnar taurine crystals, comprising the step of growing crystals in an environment where a taurine aqueous solution is mixed or brought into contact with a liquid substance with a low taurine solubility.
6. The manufacturing method according to claim 5, It is characterized in that The taurine concentration in the aqueous solution is 3 to 28 w%.
7. The manufacturing method according to claim 5 or 6, It is characterized in that The amount of the liquid substance with low taurine solubility accounts for less than 50w% of the total amount of the taurine aqueous solution.
8. The manufacturing method according to any one of claims 5 to 7, It is characterized in that The aforementioned liquid substance with low taurine solubility is a water-soluble organic solvent, and the taurine solubility of the water-soluble organic solvent is 1.0 g / 100 g of the liquid substance (25° C.) or less.
9. The manufacturing method according to claim 8, It is characterized in that The aforementioned water-soluble organic solvent is one or more selected from the group consisting of ethanol, isopropanol, ethylene glycol, 1,2-propylene glycol, 1,3-propylene glycol, 1,2-butylene glycol, 1,3-butylene glycol, isopentyl glycol, diethylene glycol, dipropylene glycol, diethylene glycol monoethyl ether, glycerol, diglycerol, triglyceride, 1,2-pentanediol, 1,2-hexanediol, cyclohexylglycerol and N-hexylglycerol.
10. A method for producing a skin external preparation component containing fine needle-shaped or columnar taurine crystals, Features Including the following processes: A step of growing crystals in an environment where the taurine aqueous solution is mixed or brought into contact with a liquid substance in which taurine has a low solubility, and A step of incorporating the fine needle-shaped or columnar taurine crystals obtained in the aforementioned crystal growth step into the aforementioned skin external preparation ingredients.
11. The manufacturing method according to claim 10, It is characterized in that The taurine concentration in the aqueous solution is 3 to 28 w%.
12. The manufacturing method according to claim 10 or 11, It is characterized in that The amount of the liquid substance with low taurine solubility accounts for less than 50w% of the total amount of the taurine aqueous solution.
13. The manufacturing method according to claim 10, It is characterized in that The aforementioned liquid substance with low taurine solubility is a water-soluble organic solvent, and the taurine solubility of the water-soluble organic solvent is 1.0 g / 100 g of the liquid substance (25° C.) or less.
14. The manufacturing method according to claim 13, It is characterized in that The aforementioned water-soluble organic solvent is one or more selected from the group consisting of ethanol, isopropanol, ethylene glycol, 1,2-propylene glycol, 1,3-propylene glycol, 1,2-butylene glycol, 1,3-butylene glycol, isopentyl glycol, diethylene glycol, dipropylene glycol, diethylene glycol monoethyl ether, glycerol, diglycerol, triglyceride, 1,2-pentanediol, 1,2-hexanediol, cyclohexylglycerol and N-hexylglycerol.
15. The manufacturing method according to claim 10, It is characterized in that The aforementioned skin external preparation component is a liquid, water, emulsion, cream or aqueous gel, and the taurine concentration in the aqueous phase of the mixing process is maintained above the saturation concentration, so that fine needle-shaped or columnar taurine crystals are maintained in the aforementioned skin external preparation component.
16. The manufacturing method according to claim 10, It is characterized in that The aforementioned external skin preparation component is a flower makeup oil or an ointment, and the fine needle-shaped or columnar taurine crystals obtained in the aforementioned crystal growth step are filtered and dried, and then incorporated into the external skin preparation component in the mixing step.
